Vitafoods Europe 2026: What Actually Mattered (And What Didn’t)
Although we did not exhibit this year, our presence a Vitafoods Europe 2026 took place on May 5–7 in Barcelona. From a distance, it presents itself as one of the central events of the supplement industry. Inside, the reality is more selective.
This was not our first visit. And that changes how you see it.
The first time you walk such an exhibition, everything feels important — ingredients, formats, branding, positioning. By the second or third time, most of that signal disappears.
What remains is not discovery. It is confirmation.
The first time you walk such an exhibition, everything feels important — ingredients, formats, branding, positioning. By the second or third time, most of that signal disappears.
What remains is not discovery. It is confirmation.
What Actually Had Value
The most useful part of this year was not new contacts. It was existing ones.
- These are not dominant trends. They are early-stage signals.
- We met companies we already work with,particularly within the supply chain of chemical raw materials entering the EU from China. These conversations are not about “finding suppliers”. They are about stability of supply, pricing pressure, documentation, and regulatory alignment. This is where manufacturing risk is actually managed.
- There were also a few format directions worth paying attention to.Vitamin and nutrient-filled lollipops continue to appear — not as novelty, but as a delivery format targeting compliance in specific user groups, especially children. Whether they scale commercially is still unclear, but the direction is consistent.
- Vitamin and nutrient-filled lollipops continue to appear —not as novelty, but as a delivery format targeting compliance in specific user groups, especially children. Whether they scale commercially is still unclear, but the direction is consistent.
These are not dominant trends. They are early-stage signals.
Ingredients:
Stability Over Innovation
We spoke with both branded ingredient suppliers and generic raw material producers. There were no real breakthroughs.
- The ingredient space is not currently driven by discovery.It is driven by re-positioning, branding, and supply chain control. The same actives appear repeatedly, often under different narratives, supported by documentation rather than genuine novelty.
- From a manufacturing perspective, this reinforces a simple constraint.The bottleneck is not ingredients. The bottleneck is how you turn them into stable, scalable products. The bottleneck is how you turn them into stable, scalable supplement formulations.
Equipment Conversations:
Where It Became Practical
The most relevant discussions this year were with equipment manufacturers.
Not because machines are fundamentally new, but because limitations are being addressed more directly.
Not because machines are fundamentally new, but because limitations are being addressed more directly.
- Topics such as dwell time, pre-compression, and material behavior under pressure are no longer treated as secondary details.They are central to whether a formulation can be produced at all.
After facing real compression challenges internally with difficult systems such as amino acid blends, these conversations were not theoretical.
They were directly applicable. - The direction is clear:equipment is evolving not to increase nominal speed, but to handle materials that previously failed in production conditions.
This aligns with our own planning, where equipment upgrades are being evaluated towards the end of 2026.
From Exhibition to Production Reality
After several visits, the exhibition pattern becomes predictable. Ingredients repeat. Formats return with new positioning.
(01)
Most presentations describe what a product could be, not how it behaves under manufacturing conditions.
Clear scope with a shared vision
This is not a flaw of the event — it reflects how the industry is structured. Concept development and production development are different disciplines, and most activity at exhibitions stays in the first.
The gap between them is where things change.
(02)
Formats like water-soluble fish oil or nutrient delivery systems look clean at concept stage.
Samples dissolve, taste is controlled, positioning is clear.
At that level, there are no visible problems. The problems start when the same system is pushed into production — under pressure, over time, at scale.
That is where variables appear: material behavior under compression, interaction between components, stability across batches, response to process parameters. These are not edge cases. They are normal conditions of manufacturing.
That is where variables appear: material behavior under compression, interaction between components, stability across batches, response to process parameters. These are not edge cases. They are normal conditions of manufacturing.
This is why the most relevant discussions at Vitafoods are not at ingredient displays.
(03)
They happen with equipment manufacturers and process specialists — where dwell time, pre-compression, and mechanical limits are discussed directly.
Not as theory, but as constraints that define whether a formulation will run or stop.
For brands, this distinction is critical.
For brands, this distinction is critical.
A formulation can be correct on paper and still fail in production. Not because the idea is wrong, but because production exposes factors that concept-stage development does not address.
This is especially visible in formats such as powder sachet production, where dosing, flowability, sealing, taste, and stability all have to work together.
This is especially visible in formats such as powder sachet production, where dosing, flowability, sealing, taste, and stability all have to work together.
Understanding that transition early is not optional. It is what determines whether a product moves forward or stalls. This is also why we continue developing our Manufacturing Insight initiative: real production conditions explain more than exhibition concepts ever can.
Final Observation
Vitafoods Europe 2026 does not lack ideas.
What it shows clearly is that most of them are still at the stage where nothing has been tested against production reality.
What it shows clearly is that most of them are still at the stage where nothing has been tested against production reality.
Ready to scale your supplement brand with a trusted European CMO ?
Get in touch to explore our contract manufacturing solutions.